Wave Life Sciences Ltd.

    • Market Cap $1.99B
    • PE -14
    • Debt $NaN
    • Cash $310.95M
    • EV $NaN
    • FCF -$141.83M

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$142.52M
    EBIT-$142.52M
    ROE-101%
    ROA-40%
    FCF-$141.83M
    Equity$141.64M
    Growth Stability1
    PE-13.98
    PB14.07
    P/FCF-14.05
    Price/Cash0.16
    Sales CAGR34%
    Equity CAGR-3%
    Earnings Growth YoY-952%
    Earnings Growth QoQ88%
    Sales CAGR 5Y36%
    Equity CAGR 5Y1%
    Earnings CAGR 3Y149%
    Sales CAGR 3Y149%
    Equity CAGR 3Y14%
    Market Cap$1.99B
    Assets$358.50M
    Cash$310.95M
    Shares Outstanding130.47M
    Working Capital153.79M
    Current Ratio1.9
    Shares Growth 3y39%
    Equity Growth QoQ-4K%
    Equity Growth YoY-450%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

    SEC Filings

    Direct access to Wave Life Sciences Ltd. (WVE) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2024
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2023
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2022
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31

    Sector Comparison

    How does Wave Life Sciences Ltd. compare to its competitors?

    Loading chart...

    Peter Lynch's Chart

    This chart shows the current pricing of Wave Life Sciences Ltd. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Wave Life Sciences Ltd. Discounted Cash Flow

    Fully customizable DCF calculator online for Wave Life Sciences Ltd..

    = -$1.4B
    012345678910TV
    fcf-$142M-$142M-$142M-$142M-$142M-$142M-$142M-$142M-$142M-$142M-$142M-$1.4B
    DCF-$129M-$117M-$107M-$97M-$88M-$80M-$73M-$66M-$60M-$55M-$547M
    Value-$1.4B

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
    Net Margins--13K%-4K%-3K%-1K%-1K%-747%-298%-4K%-51%-
    ROA--12%-33%-56%-50%-68%-54%-59%-110%-21%-40%
    ROE--13%-41%-73%-200%-304%-181%-376%359%-145%-101%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
    Debt over FCF-----------
    Debt over Equity-----------
    Growth Stability----------1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
    Revenue YoY growth--877%149%289%11%26%104%-91%3K%36%
    Earnings YoY growth-267%190%83%44%32%-23%-18%32%-64%-
    Equity YoY growth-7K%-12%4%-48%-13%30%-61%-239%-188%1%
    FCF YoY growth-187%160%174%-68%486%-39%-24%44%-84%-